Articles

The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia

Hematology Research Unit, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland
University of Virginia Cancer Center, Charlottesville, VA, USA
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Institute for Molecular Medicine (FIMM), University of Helsinki, Finland
Institute for Molecular Medicine (FIMM), University of Helsinki, Finland
Department of Clinical Chemistry and TYKSLAB, University of Turku and Turku University Central Hospital, Finland
Adaptive Biotechnologies Corp, Seattle, WA, USA
Institute for Molecular Medicine (FIMM), University of Helsinki, Finland
Institute for Molecular Medicine (FIMM), University of Helsinki, Finland
Hematology Research Unit, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain
Hematology Research Unit, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
University of Virginia Cancer Center, Charlottesville, VA, USA
Hematology Research Unit, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland
Vol. 100 No. 1 (2015): January, 2015 https://doi.org/10.3324/haematol.2014.113142